Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

J&J, GSK, AstraZeneca's Emerging Markets Roundup: PharmAsia News Earnings Call Roundup

This article was originally published in PharmAsia News

Executive Summary

Quarterly earnings calls seem lacking these days unless a company references its plans for emerging markets. PharmAsia News combs through quarterly earnings reports to spot developing trends in emerging market strategies.

You may also be interested in...



Invida Goes Deeper In Skincare, Teams With Sinclair To Expand In Asia Pacific

UK specialty drug maker Sinclair signed a collaborative deal Dec. 7 with Singapore-based Invida to commercialize a number of dermatology products in 11 Asian markets. While multinational drug makers are accelerating expansion in Asia, specialty pharmaceutical companies are teaming up with contract sales firms such as Invida to capitalize on increasing demand in the region

Invida Goes Deeper In Skincare, Teams With Sinclair To Expand In Asia Pacific

UK specialty drug maker Sinclair signed a collaborative deal Dec. 7 with Singapore-based Invida to commercialize a number of dermatology products in 11 Asian markets. While multinational drug makers are accelerating expansion in Asia, specialty pharmaceutical companies are teaming up with contract sales firms such as Invida to capitalize on increasing demand in the region

GSK India Managing Director Hasit Joshipura On Business Dynamics In India, Tiered Pricing And Approaches To Rural Markets: An Interview With PharmAsia News (Part 2 Of 2)

Hasit Joshipura, GlaxoSmithKline's India Managing Director is unfazed by the recent mega-deal that Abbott struck with Piramal Healthcare - catapulting the U.S. giant to the number one slot in India with a market share of nearly 7 percent.

Related Content

UsernamePublicRestriction

Register

SC073990

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel